TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03950752

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimized Bagel
Description: Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bagel
Description: Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
Study: NCT01345864

Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil Placebo + PF-04995274 Placebo
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil 5 mg + PF-04995274 Placebo
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil 10mg + PF-04995274 Placebo
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
Study: NCT04498637

Intervention type: OTHER
Intervention: 'Attitudes towards people with disability Scale'
Description: The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.

Intervention type: OTHER
Intervention: 'Attitudes towards people with disability Scale'
Description: The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.
Study: NCT02053493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate
Description: Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo
Study: NCT02084901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting biodegradable stent Orsiro implantation
Description: Drug-eluting biodegradable stent Orsiro implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
Description: Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
Study: NCT01820247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteral nutrition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteral nutrition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides
Study: NCT01475903

Intervention type: PROCEDURE
Intervention: Longitudinal sleeve gastrectomy
Description: The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
Study: NCT04292067

Intervention type: BIOLOGICAL
Intervention: Faecal sampling
Description: Faecal sampling at baseline

Intervention type: BIOLOGICAL
Intervention: Faecal sampling
Description: Faecal sampling at baseline

Intervention type: BIOLOGICAL
Intervention: Faecal sampling
Description: Faecal sampling at baseline
Study: NCT03160040

Intervention type: DRUG
Intervention: Minocycline IV
Description: This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
Study: NCT04086810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration
Study: NCT02269839

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
Study: NCT02438189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemia Minimization Algorithm
Description: The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
Study: NCT02567383

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia; Thermotron RF-8
Description: 40 minutes within 2hr after irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2 per week for 6 weekly cycles before radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 10-12mg/m2 per week for 6 weekly cycles before radiotherapy
Study: NCT02732808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation stimulation
Description: Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection.
Study: NCT00543114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously on Day 1 of each 28 day cycle
Study: NCT04634188

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin
Description: Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin
Description: Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin
Description: Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
Study: NCT02143219

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatine
Description: Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid
Description: Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
Study: NCT03766477

Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index (IQSP) and Johansson
Description: All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Smartphone APP
Description: All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
Study: NCT02143219

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~* Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~* Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance.

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~* If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~* If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course.
Study: NCT05558397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Group (Epidural morphine)
Description: Implantation of an epidural catheter for administration of morphine and ropvacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Oral morphine)
Description: Oral administration of morphine, pregabalin or duloxetin
Study: NCT03504618

Intervention type: DRUG
Intervention: FOLFOXIRI
Description: Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day
Study: NCT03383991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse Total Shoulder Arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Study: NCT01619865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET/CT
Description: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
Study: NCT01494818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide-based contact lens care system
Study: NCT03766477

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
Study: NCT04896424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cryoballoon-based pulmonary veins isolation
Description: A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases \< -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation\<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
Study: NCT03480932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alfa-2a
Description: Antiviral agent used for the treatment of hepatitis C
Study: NCT00254826

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: YF-VAX® plus saline
Description: YF-VAX® plus saine
Study: NCT01494818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHMB-containing contact lens solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Description: Contact lenses identical to habitual prescription worn per usual replacement regimen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft contact lenses
Description: Contact lenses identical to habitual prescription worn per usual replacement regimen
Study: NCT03215537

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive intervention
Description: preoperative and postoperative exercise program
Study: NCT02240017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
Study: NCT00254826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 17D YF Vaccine plus Ig,
Description: 17D YF Vaccine plus Ig, one vaccine on day 0
Study: NCT04654637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Strategies
Description: Multiple Interactive with Nutrition and Exercise Strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Strategies
Description: Multiple Interactive with Nutrition and Exercise Strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Strategies
Description: Multiple Interactive with Nutrition and Exercise Strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Strategies
Description: Multiple Interactive with Nutrition and Exercise Strategies
Study: NCT02240017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fractionated Cisplatin
Description: Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
Study: NCT02535039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg \* d for application to the third day after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: The same volume of physiological saline will be given in Placebo group
Study: NCT02771821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operative groups based on methodology of problematization
Description: The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months.
Study: NCT03711032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
Study: NCT01569126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY110140
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY110140
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY110140
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY110140
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY110140
Description: Administered orally as capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
Study: NCT00791999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 400mg
Description: 400mg CDP870 given every 2 weeks until Week22 (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 200mg
Description: 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP870 100mg
Description: 200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CDP870
Description: given every 2 weeks until Week22 (SC)
Study: NCT01572402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bagueutte Cheese Gourmet (Crocodille)
Description: 180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagueutte Cheese Gourmet (Crocodille)
Description: 180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
Study: NCT03711032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy